Patent ID: 8501816

Claim:
An antitussive oral lozenge comprising: about 6-35 mg of memantine, or a pharmaceutically acceptable salt thereof; menthol; an alkalinizing agent comprising sodium carbonate and sodium bicarbonate at a weight ratio of about 1:1 to about 1:10, in an amount sufficient to raise the pH of the oral cavity, after buccal or sublingual administration, to a pH of 7.8 or higher for at least about 2 minutes; and one or more excipients selected from the group consisting of a binder, one or more sugar or sugar substitutes, a filler, a disintegrant, a lubricant, and combinations thereof; wherein after a single buccal or sublingual administration to a patient, said oral lozenge provides: i) a memantine T max ranging from about 15 minutes to about 5.5 hours; ii) a memantine C max ranging from about 1 ng/mL to about 2.5 ng/mL per mg dosed; iii) a memantine AUC 0-∞ ranging from about 600 ng-hr/mL to about 5,000 ng-hr/mL and; iv) an absorption rate of memantine that is higher than the absorption rate of said composition that does not include an alkalinizing agent.